Welcome to the European Association for Cancer Research
Europe’s membership association for cancer researchers

LIF As We Know It: From Basic Science to Clinical Trials

Barcelona, Spain : 28 - 29 May 2018


We are living in very exciting times in the context of molecular oncology. A deeper understanding of the molecular mechanisms involved in cancer is revealing novel therapeutic approaches to treating cancer. A new and exciting therapeutic target has emerged recently. LIF (Leukemia Inhibitory Factor) is a cytokine aberrantly expressed in cancer that acts as a pleiotropic oncogenic factor. It regulates cancer stem cells, the tumour microenvironment and specifically the immune system.

In this conference, we will learn about the most recent advances in the field of LIF from the basic science to clinical studies including the understanding of its biology, its implications in cancer and the development of anti-cancer agents.

Target audience

The target audience for this conference is basic and translational scientists and clinicians, both senior and young investigators that want to have a broad and detailed overview of the most recent advances in the field of LIF.

Topics to be covered

  • Embryonic stem cells
  • Immunomodulation
  • Therapeutic target in cancer
  • Drug development

Scientific Organiser: Joan Seoane


Key dates

Bursary application deadline:
26 March 2018

Registration deadline:
30 April 2018

Sorry. You need to upgrade your browser

You are using Internet Explorer 8

This is considered an out of date browser. This website has been developed with modern browsers in mind to allow it to display at its best in a wide variety of viewing situations - including mobile viewing. But we haven't supported older browsers like IE8. Please upgrade to the latest version of Internet Explorer - or try Mozilla Firefox or Google Chrome. Both are excellent browsers.

Thank you.